RYZ-101 is under clinical development by RayzeBio and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase I drugs for Small-Cell Lung Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RYZ-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RYZ-101 overview

RYZ-101 is under development for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), extensive stage small cell lung cancer, relapsed and refractory multiple myeloma (MM). The drug candidate is an actinium-225 radiolabeled conjugated synthetic peptide somatostatin analog (SSA) which acts by targeting cell expressing somatostatin receptor 2 (SSTR2). It is administered parenterally and intravenously.

RayzeBio overview

RayzeBio is a biotechnology company that aims to improve clinical benefit by efficiently developing innovative tumor-targeted small-molecule medicines that harness the power of radioisotopes. It is headquartered in San Diego, California, the US.

For a complete picture of RYZ-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.